Biotech VCs Are Having an Identity Crisis

Novartis CEO Vas Narasimhan captured the anxiety at the 2026 World Economic Forum, warning that Chinese biotech companies can use AI to churn out fast-follower medicines at unprecedented speed. He called for stronger U.S. patent protections and a more streamlined FDA to keep pace.

AI Is Stealing the Spotlight (and the Checks)

While China eats into the cost side of the equation, AI is attacking the other end: where investor dollars flow.

Traditional drug development is brutally inefficient. The average approved drug costs about $2.6 billion when you factor in all the failures along the way. Timelines stretch 10 to 15 years. And the overall success rate from discovery to FDA approval? Somewhere between 7% and 12%, depending on who's counting. It's like placing a bet at a casino where the house edge keeps getting worse.

AI-driven drug discovery companies are pitching a different story. Firms like Recursion, Insilico Medicine, and Absci are compressing discovery timelines, racing to IND filings (the application that lets you start testing a drug in humans) at record pace. The year 2025 saw the biggest single-year jump in IND applications for AI-originated molecules.

Insilico signed over 10 new pharma deals in 2025 alone, totaling $1.3 billion in fresh commitments and pushing its cumulative deal value to $4.6 billion. It now serves 13 of the top 20 pharmaceutical companies. Its software revenue grew nearly 24%, with subscriptions climbing over 18%. That's not a biotech business model; that's a SaaS company wearing a lab coat.

For VCs, this changes the math. Traditional biotech investments are binary bets: the drug works or it doesn't, and you might wait a decade to find out. AI platforms generate recurring software revenue, predictable milestone payments, and non-dilutive pharma partnerships that reduce dependence on follow-on venture rounds. It's the difference between buying a lottery ticket and buying an apartment building.

Naturally, limited partners are paying attention. Firms like Andreessen Horowitz and Sequoia have piled into AI-bio companies, and mega-rounds are becoming common. Enveda closed a $150 million Series D in 2025, pushing its total funding past half a billion dollars at a $1 billion valuation.

The VC Response: Adapt or Get Left Behind

So how are biotech VCs reacting? The smart ones are evolving. Fast.

The first shift is geographic diversification. LPs are steering money toward specialist funds outside the traditional Boston and San Francisco hubs: Catalio raised over $400 million in New York, Sofinnova built a €1.2 billion platform in Europe, and Hatteras pulled in more than $200 million focused on the Research Triangle. The old playbook of parking all your money on Kendall Square is getting a rewrite.

The second shift is moving earlier in the process. VCs are embedding themselves in academic labs, courting scientists before their research is even published. If Chinese competitors can license promising early-stage assets at a fraction of the cost, American VCs need to get there first or find angles that can't be replicated cheaply overseas.

The third shift is a growing appetite for pharma-VC hybrid models. Eli Lilly partnered with Andreessen Horowitz on joint investments, blurring the line between corporate venture and traditional VC. These collaborations give startups both capital and a built-in commercialization partner.

Despite all the hand-wringing, money is still flowing. The back half of 2025 roared: Q3 venture financing surged nearly 71%, jumping from $1.8 billion to $3.1 billion. LPs aren't abandoning biology; they're just getting pickier about who they back, favoring experienced managers with strong track records over broad, spray-and-pray approaches.

What This Means for the Rest of Us

The biotech VC shakeup isn't just an inside-baseball story for finance types. It has real consequences for patients.

If AI genuinely compresses drug discovery timelines, treatments could reach patients years sooner. If Chinese competition forces the U.S. to streamline its own regulatory process (the FDA has already proposed speeding up domestic trials), that's a win for everyone waiting on a new therapy.

But there are risks, too. The U.S. Biosecure Act, enacted in December 2025, could restrict partnerships with Chinese firms and raise costs for American biotechs that depend on overseas manufacturing, though its prohibitions are not expected to take full effect until 2028 at the earliest. If capital keeps chasing AI platforms over traditional drug development, important but less "sexy" therapeutic areas could get starved for funding.

The biotech VC model isn't dying. But it's being forced to grow up, and fast. The investors who figure out how to blend AI's efficiency, China's cost advantages, and good old-fashioned scientific rigor will define the next era of drug development. Everyone else will be telling stories about the good old days.

The CAR-T Startup Betting $110M It Can Crack Liver Cancer

A Shanghai biotech just raised $110 million to chase what nobody has achieved: a CAR-T therapy that actually works against solid tumors. Oricell Therapeutics is betting it can crack liver cancer and IPO on the other side.